GlassScriptPhysician profile
Jessica E Liggett
NPI 1619179710
$8,078.17
in general payments reported to CMS, 2019-2025
39 companies · $1,816 in 2025
The $1,816 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,197 · 2020: $785 · 2021: $899 · 2022: $1,019 · 2023: $1,199 · 2024: $1,164 · 2025: $1,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,886 · Education: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,886.35 |
| Education | $292.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,629.64 | 2019-2025 | |
| Janssen Biotech, INC. | $1,182.29 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Ucb, INC. | $546.09 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $527.73 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $491.71 | 2019-2025 | Dupixent |
| Amgen INC. | $424.97 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $406.87 | 2021-2025 | Opzelura |
| Genzyme Corporation | $383.08 | 2019-2025 | |
| Lilly USA, LLC | $329.99 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $308.89 | 2019-2025 | Blu-U, Odomzo, Ilumya |
| Pfizer INC. | $258.28 | 2019-2025 | |
| Leo Pharma INC. | $188.48 | 2019-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $161.63 | 2019-2024 | Siliq |
| Vyne Pharmaceuticals INC. | $144.57 | 2020-2021 | |
| Celgene Corporation | $118.01 | 2019 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $112.48 | 2021-2024 | Xolair, Erivedge |
| Arcutis Biotherapeutics, INC. | $81.99 | 2023-2025 | Zoryve |
| Organogenesis INC. | $81.73 | 2023-2025 | Via Matrix, Puraply, Cygnus Dual |
| Fresenius Kabi USA, LLC | $80.05 | 2023-2024 | Idacio |
| Allergan, INC. | $52.03 | 2019-2021 | |
| Kyowa Kirin, INC. | $49.39 | 2022-2025 | Poteligeo |
| Prugen, INC. Pharmaceuticals | $48.61 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.62 | 2022-2025 | Spevigo |
| Journey Medical Corporation | $44.67 | 2022-2023 | |
| Epi Health, LLC | $44.59 | 2019-2020 | |
| Galderma Laboratories, L.P. | $43.53 | 2020-2025 | Nemluvio |
| Almirall LLC | $43.09 | 2020-2023 | Seysara |
| Biofrontera INC. | $36.27 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Sandoz INC. | $34.08 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $28.59 | 2019 | |
| Mimedx Group, INC. | $26.26 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $20.31 | 2023 | |
| Kerecis Limited | $19.30 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Paratek Pharmaceuticals, INC. | $15.91 | 2021 | |
| Lnhc, INC | $15.69 | 2025 | Zelsuvmi |
| Helsinn Therapeutics (U.S.), INC. | $13.58 | 2023 | Valchlor |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Dermira, INC. | $12.92 | 2020 | |
| Melinta Therapeutics, LLC | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Liggett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.